Recent studies have reported that a fraction of patients treated with combinations of ICI have an increased risk of severe immune-related adverse events such as myocarditis, a severe cardiac complication, due to the expression of some ICs, such as PD-1 and PD-L1 [40,41], in the myocardium. The gene discussed is PDCD1; the disease is myocarditis.